Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 325

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases

Open access
Prins, Christa, Kerdel, Francisco A., Padilla, R. Steven, Hunziker, Thomas, Chimenti, Sergio, Viard, Isabelle, Mauri, Davide N., Flynn, Kirsten, Trent, Jennifer, Margolis, David J., Saurat, Jean-Hilaire, French, Lars E., for the TEN-IVIG Study Group·2003·Archives of Dermatology

Abstract

OBJECTIVE: To evaluate the effect of high-dose intravenous immunoglobulin (IVIG) in toxic epidermal necrolysis (TEN), parameters that may affect response to treatment, and the effect of different IVIG batches on Fas-mediated cell death. DESIGN: Multicenter retrospective analysis of 48 consecutive TEN patients treated with IVIG. SETTING: Fourteen university hospital dermatology centers in Europe and the United States. PATIENTS: Forty-eight patients with TEN (skin detachment >10% of their body surface [mean, 44.8%; range, 10%-95%]). INTERVENTIONS: Infusion of IVIG in all patients (range, 0.8-5.8 g/kg), and analysis of the ability of different IVIG batches to inhibit Fas-mediated cell death. MAIN OUTCOME MEASURES: Objective response to IVIG treatment, final outcome at day 45, parameters that may affect response to IVIG treatment, and tolerance. RESULTS: Infusion of IVIG (mean total dose, 2.7 g/kg [range, 0.65-5.8 g/kg]; mean consecutive days, 4 [range, 1-5 days]) was associated with a rapid cessation (mean, 2.3 days [range, 1-6 days]) of skin and mucosal detachment in 43 patients (90%) and survival in 42 (88%). Patients who responded to IVIG had received treatment earlier in the course of disease and, on average, higher doses of IVIG. Furthermore, analysis of 35 IVIG batches revealed significant batch-to-batch variations in the capacity of IVIG to inhibit Fas-mediated cell death in vitro. CONCLUSIONS: Early infusion of high-dose IVIG is safe, well tolerated, and likely to be effective in improving the survival of patients with TEN. We recommend early treatment with IVIG at a total dose of 3 g/kg over 3 consecutive days (1 g/kg per day for 3 days).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/archderm.139.1.26

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 325

Metadata

Authors
Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., Saurat, J.-H., French, L. E., & for the TEN-IVIG Study Group
Venue
Archives of Dermatology
Published
2003-01-01
Volume
139
Issue
1
Pages
26
ISSN
0003-987X (ISSN-L)
OpenAlex
W2121050460
Cited by
325
References
20
FWCI
18.95
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases. https://app.cochat.ai/papers/10.1001/archderm.139.1.26
The paper
Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., Saurat, J.-H., French, L. E., & for the TEN-IVIG Study Group. (2003). Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases. Archives of Dermatology. https://doi.org/10.1001/archderm.139.1.26

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.